Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell is also preparing Fast CAR therapies for NHL and other haematological cancers such as multiple myeloma (MM). ... of relapse – another challenge with CAR-T therapies.

Latest news

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    CAR-T cell therapies, the most clinically established form of ACT, can recognise only the specific antigens on the surface of cancer cells. ... It also  acquired CAR-T specialist Juno therapeutics for $9bn in 2018, giving it rights to lead CAR-T

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Fedratinib was one of the late-stage development programmes highlighted by BMS when the merger was announced in January, although others – such as multiple sclerosis drug ozanimod and CAR-T cancer ... therapies – are thought to have greater sales

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    BlueRock is also developing iPSCs that differentiate into microglia, oligodendrocytes and eneic neurons for neurology applications, cardiomyocytes for heart failure, as well as macrophages and T regulatory cells for immunology applications

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    region. The last 12 months have seen the European approval and launch of groundbreaking therapies in the field, most notably the first two CAR-T therapies, Novartis’ Kymriah and ... The next therapy area which could be transformed by cell therapy is

  • Syncona start-up Quell Therapeutics appoints chief exec Syncona start-up Quell Therapeutics appoints chief exec

    Biotech focusing on Tregs. Quell Therapeutics, a new UK biotech company focused on developing engineered T regulatory (Treg) cell therapies, has appointed Iain McGill as its chief executive. ... They work by downregulating the immune system, rather than

More from news
Approximately 3 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies. ... therapies, where the administration is not as simple as

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... Manufacturing of CAR-T cell therapies is a highly sophisticated,

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics